Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation
| dc.creator | Jääskeläinen, AJ | |
| dc.creator | Kuivanen, S | |
| dc.creator | Kekäläinen, E | |
| dc.creator | Ahava, MJ | |
| dc.creator | Loginov, R | |
| dc.creator | Kallio-Kokko, H | |
| dc.creator | Vapalahti, O | |
| dc.creator | Jarva, H | |
| dc.creator | Kurkela, S | |
| dc.creator | Lappalainen, M | |
| dc.date.accessioned | 2020-07-29T20:45:36Z | |
| dc.date.available | 2020-07-29T20:45:36Z | |
| dc.date.created | 2020-06-14 | |
| dc.description.abstractenglish | There is an urgent need for reliable high-throughput serological assays for the management of the ongoing COVID-19 pandemic. Preferably, the performance of serological tests for a novel virus should be determined with clinical specimens against a gold standard, i.e. virus neutralisation. We compared the performance of six commercial immunoassays for the detection of SARS-COV-2 IgG, IgA and IgM antibodies, including four automated assays [Abbott SARS-COV-2 IgG (CE marked), Diasorin Liaison® SARS-COV-2 S1/S2 IgG (research use only, RUO), and Euroimmun SARS-COV-2 IgG and IgA (CE marked)], and two rapid lateral flow (immunocromatographic) tests [Acro Biotech 2019-nCoV IgG/IgM (CE marked) and Xiamen Biotime Biotechnology SARS-COV-2 IgG/IgM (CE marked)] with a microneutralisation test (MNT). Two specimen panels from serum samples sent to Helsinki University Hospital Laboratory (HUSLAB) were compiled: the patient panel (N=70) included sera from PCR confirmed COVID-19 patients, and the negative panel (N=81) included sera sent for screening of autoimmune diseases and respiratory virus antibodies in 2018 and 2019. The MNT was carried out for all COVID-19 samples (70 serum samples, 62 individuals) and for 53 samples from the negative panel. Forty-one out of 62 COVID-19 patients showed neutralising antibodies.The specificity and sensitivity values of the commercial tests against MNT, respectively, were as follows: 95.1 %/80.5 % (Abbott Architect SARS-CoV-2 IgG), 94.9 %/43.8 % (Diasorin Liaison SARS-CoV-2 IgG; RUO), 68.3 %/87.8 % (Euroimmun SARS-CoV-2 IgA), 86.6 %/70.7 % (Euroimmun SARS-CoV-2 IgG), 74.4 %/56.1 % (Acro 2019-nCoV IgG), 69.5 %/46.3 % (Acro 2019-nCoV IgM), 97.5 %/71.9 % (Xiamen Biotime SARS-CoV-2 IgG), and 88.8 %/81.3 % (Xiamen Biotime SARS-CoV-2 IgM). This study shows variable performance values. Laboratories should carefully consider their testing process, such as a two-tier approach, in order to optimize the overall performance of SARS- CoV-2 serodiagnostics. | spa |
| dc.format.extent | 10 páginas | spa |
| dc.format.mimetype | application/pdf | spa |
| dc.identifier.doi | https://doi.org/10.1016/j.jcv.2020.104512 | spa |
| dc.identifier.issn | 1386-6532 | spa |
| dc.identifier.other | https://www.sciencedirect.com/science/article/pii/S1386653220302547?via%3Dihub#kwd0005 | spa |
| dc.identifier.uri | https://hdl.handle.net/20.500.12010/11378 | |
| dc.publisher | Journal of Clinical Virology | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.source | reponame:Expeditio Repositorio Institucional UJTL | spa |
| dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | spa |
| dc.subject | Serology | spa |
| dc.subject | IgG | spa |
| dc.subject | IgA | spa |
| dc.subject | Neutralisation | spa |
| dc.subject.lemb | Síndrome respiratorio agudo grave | spa |
| dc.subject.lemb | COVID-19 | spa |
| dc.subject.lemb | SARS-CoV-2 | spa |
| dc.subject.lemb | Coronavirus | spa |
| dc.title | Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation | spa |
| dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
| dc.type.local | Artículo | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- Performance-of-six-SARS-CoV-2-immunoassays-in-compari_2020_Journal-of-Clinic.pdf
- Tamaño:
- 1.67 MB
- Formato:
- Adobe Portable Document Format
- Descripción:
- Documento Reservado
Bloque de licencias
1 - 1 de 1
Cargando...
- Nombre:
- license.txt
- Tamaño:
- 2.87 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción:
